1. Home
  2. OFS vs ACET Comparison

OFS vs ACET Comparison

Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$4.66

Market Cap

67.1M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.00

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFS
ACET
Founded
2001
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
71.3M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
OFS
ACET
Price
$4.66
$8.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
63.5K
184.4K
Earning Date
03-02-2026
03-05-2026
Dividend Yield
13.68%
N/A
EPS Growth
N/A
N/A
EPS
0.24
N/A
Revenue
$42,970,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.44
$7.15
52 Week High
$9.80
$17.44

Technical Indicators

Market Signals
Indicator
OFS
ACET
Relative Strength Index (RSI) 42.87 64.65
Support Level $4.91 $8.18
Resistance Level $5.01 $9.00
Average True Range (ATR) 0.22 0.48
MACD -0.01 -0.29
Stochastic Oscillator 6.45 16.41

Price Performance

Historical Comparison
OFS
ACET

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: